Wildfires are an ancient force shaping the environment, but they have grown in frequency, range and intensity in response to a changing climate. At ORNL, scientists are working on several fronts to better understand and predict these events and what they mean for the carbon cycle and biodiversity.
Scientist-inventors from ORNL will present seven new technologies during the Technology Innovation Showcase on Friday, July 14, from 8 a.m.–4 p.m. at the Joint Institute for Computational Sciences on ORNL’s campus.
As part of a multi-institutional research project, scientists at ORNL leveraged their computational systems biology expertise and the largest, most diverse set of health data to date to explore the genetic basis of varicose veins.
When Hurricane Maria battered Puerto Rico in 2017, winds snapped trees and destroyed homes, while heavy rains transformed streets into rivers. But after the storm passed, the human toll continued to grow as residents struggled without electricity for months. Five years later, power outages remain long and frequent.
ORNL and the Tennessee Valley Authority, or TVA, are joining forces to advance decarbonization technologies from discovery through deployment through a new memorandum of understanding, or MOU.
A team of scientists from LanzaTech, Northwestern University and ORNL have developed carbon capture technology that harnesses emissions from industrial processes to produce acetone and isopropanol
Three ORNL scientists have been elected fellows of the American Association for the Advancement of Science, or AAAS, the world’s largest general scientific society and publisher of the Science family of journals.
The Department of Energy’s Office of Science has selected five Oak Ridge National Laboratory scientists for Early Career Research Program awards.
Six scientists at the Department of Energy’s Oak Ridge National Laboratory were named Battelle Distinguished Inventors, in recognition of obtaining 14 or more patents during their careers at the lab.
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.